Altimmune stock: buy or sell?
March 31st, 2020
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, designs and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer.
Should I buy Altimmune stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Altimmune stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Altimmune stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for ALT stock for the last 30 days.
Altimmune stock analysis
Shares of Altimmune boosted a super good 6.29% and closed at $3.21.
Altimmune boosted a super good 6.29% and closed at $3.21. Since price and SMA200d lines crossed up on February 28th, ALT climbed $1.45 (82.39%). Since Mar 2nd when SMA50d and SMA100d crossed up, ALT price slipped $-0.49 per share (-13.24%).
Altimmune shares boosted 12.63% this week, ending at $3.21. Early March ALT plunged a scary -31.49% in just one week.
In a weekly time frame, Altimmune stock is drawing an uptrend with rising tops and bottoms. Now trading in between its last bottom and last top, ALT might consolidate in a flat-base, waiting to break out over or down under . Last week, SMA20w and SMA40w crossed up triggering a rise of 9.18%. Since late February when ALT stock price broke up the SMA40w line, it gained $1.45 (82.39%).
Altimmune stock price history
Altimmune IPO was on January 4th, 2000 at $13.75 per share1. Since then, ALT stock sliced a -76.70%, with a yearly average of -3.80%.
1: Adjusted price after possible price splits or reverse-splits.
Altimmune stock historical price chart
ALT stock reached 52-week highs on February/28 at $4.45, and all-time highs 2013-08-27 with a price of 2175.
Altimmune stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we have not detected any price target for Altimmune stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per Share, when Altimmune posted its last earnings report, it . As soon as we get its posted EPS from the earnings report, we will extend this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a rough decrease of -3.79% to $10.33 M dollars. When comparing 2018 vs 2017, nonetheless, profit margin (that is, the net income divided by revenues) skyrocketed a 53.18% to -379.15%.
|2013||$17,913 M||-||$0.00 M0.0%||-|
|2014||$10 M||-99.94%||$-9.96 M-97.7%||0.00%|
|2015||$11 M||4.42%||$-3.44 M-32.3%||-65.44%|
|2016||$5.23 M||-50.85%||$194 M3706.4%||-5,734.13%|
|2017||$11 M||105.31%||$-46.43 M-432.3%||-123.95%|
|2018||$10 M||-3.79%||$-39.17 M-379.2%||-15.63%|
Quarterly financial resultsAltimmune posted $2.59 M in sales for 2018-Q4, a -1.74% decline compared to previous quarter. Reported quarter earnings marked $-24.51 million with a profit margin of -946.73%. Profit margin plunged a -857.48% compared to previous quarter when profit margin was -89.25%. When comparing revenues to same quarter last year, Altimmune sales marked a godawful loss and eased a -7.84%.
|2017-Q1||$804 M||-||$0.00 M0.0%||-|
|2017-Q2||$2,533 M||215.05%||$0.00 M0.0%||0.00%|
|2017-Q3||$5 M||-99.82%||$-29.91 M-651.3%||0.00%|
|2017-Q4||$3 M||-38.83%||$-8.83 M-314.4%||-70.47%|
|2018-Q1||$3 M||-4.20%||$-3.17 M-117.9%||-64.06%|
|2018-Q2||$2 M||-10.18%||$-9.14 M-378.1%||187.97%|
|2018-Q3||$3 M||8.99%||$-2.35 M-89.2%||-74.27%|
|2018-Q4||$3 M||-1.74%||$-24.51 M-946.7%||942.37%|
Altimmune ownershipWhen you are planning to invest in a stock, it's always worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Altimmune, 0.00% of all outstanding shares are owned by its staff.
In case of Altimmune stock, 1.67% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ALT stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$49.2 M|
|Total shares||15.3 M|
|Float shares||12.7 M|
|- Institutional holdings (%)||1.7%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Tuesday, March 31st, 2020|
|Day range||$2.85 - $3.28|
|Average true range||$0.46|
|50d mov avg||$2.40|
|100d mov avg||$2.10|
|200d mov avg||$2.13|
Altimmune performanceTo better understand Altimmune performance you must compare its gains with other related stocks in same sector or industry. For Altimmune, the comparison is made against .